11.2019October 4, 2019|In Portfolio news|By Ventac PartnersVentac Partners portfolio company RhoVac announced that the first patient has been screened for the company’s clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 (“BRaVac”). For more information please follow this link.
